Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy  

作　　者：Pengcheng Zhao Longyan Xie Lei Yu Ping Wang 

机构地区：[1]School of Life Sciences and Medicine,Shandong University of Technology,Zibo,Shandong 255000,China [2]Tongji University Cancer Center,Shanghai Tenth People's Hospital,School of Medicine,Tongji University,Shanghai 200092,China

出　　处：《Genes & Diseases》2024年第1期205-217,共13页基因与疾病（英文）

基　　金：supported by the National Key Research and Development Program of China(No.2020YFA0803201);the National Natural Science Foundation of China(No.31830053,31920103007,22207084);the Fundamental ResearchFunds fortheCornellUniversity(No.22120220463).

摘　　要：The interaction between cluster of differentiation 47(CD47)and signal regulatory proteinα(SiRPa)protects healthy cells from macrophage attack,which is crucial for maintain-ing immune homeostasis.Overexpression of CD47 occurs widely across various tumor cell types and transmits the"don't eat me"signal to macrophages to avoid phagocytosis through binding to SIRPa.Blockade of the CD47-SIRPa axis is therefore a promising approach for cancer treat-ment.Lymphoma is the most common hematological malignancy and is an area of unmet clin-ical need.This review mainly described the current strategies targeting the CD47-SIRPa axis,including antibodies,SiRPaFc fusion proteins,small molecule inhibitors,and peptides both in preclinical studies and clinical trials with Hodgkin lymphoma and non-Hodgkin lymphoma.

关 键 词：Cancer treatment CD47-SIRPαaxis Hodgkin lymphoma IMMUNOTHERAPY Non-Hodgkin lymphoma 

分 类 号：R730.51[医药卫生—肿瘤] R733[医药卫生—临床医学]